1. Introduction {#s0005}
===============

The detection of allergen-specific IgE, along with the patient's chief complaints and medical history, is diagnostically valuable for allergic diseases, such as allergic rhinitis, atopic dermatitis, and asthma [@bib1], [@bib2]. Although in vivo skin test has been traditionally used in the clinical environments, there are several limitations of in vivo skin test including error-prone results in patients with anti-histamine medication or skin diseases such as dermographism, possibility of subjective interpretation, and the lack of standardization for protocols [@bib3], [@bib4]. Therefore, in vitro allergen-specific IgE measurements have been developed using various principles of radioimmunoassay, enzyme immunoassay, fluorescent enzyme immunoassay, immunoblot, and chemiluminescent assay [@bib5], [@bib6], [@bib7].

Among the commercially available in vitro allergy tests, multiple allergen simultaneous tests (MAST) have been continuously developed with the improvements in smaller amounts of serum consumption, shorter turnaround time, and wider spectrum of allergens included in the test [@bib6], [@bib8], [@bib9], [@bib10], [@bib11], [@bib12]. Since the difference in prevalence of allergic diseases according to age, sex, and ethnicity is prominent, the selection of multiple allergen screening panels should be modified in the context of geographical regions and race of the target populations [@bib13], [@bib14], [@bib15]. At the same time, the change of environmental substances in modern society must be considered for the progressive development of MAST assays [@bib16].

Moreover, there is no appropriate medical evidence to define any assay as the standardized reference method due to variability of allergen original materials, extraction methods, attachment processes, and detection techniques [@bib5]. Therefore, it is very difficult to analyze true sensitivity, specificity, positive predictive value, and negative predictive value of a specific MAST assay. Nevertheless, actual comparison of new MAST assay with currently used MAST assays can appropriately provide important information in the practical clinical settings.

Recently, two fully automated analyzers with high-throughput were developed and introduced in the market; AdvanSure Allostation Smart II which is the upgraded version of previous AdvanSure AlloScreen by LG Life Science, and PROTIA Allergy-Q which was newly developed by ProteomeTech. Herein, we compared the diagnostic performances of these assays with two most commonly used MAST assays in Korea, today. In addition, we evaluated propensity of each assay to give positive results for certain allergen, which we defined as "positive propensity".

2. Methods {#s0010}
==========

2.1. Study participants {#s0015}
-----------------------

We randomly selected the study samples from MAST assay requested serum samples of patients who visited Severance Hospital with symptoms of allergy including urticaria, sneezing, and itching for diagnosis of allergic disease in all age ranges. Additionally, we excluded patients with chronic comorbid diseases such as autoimmunity, malignancy, chronic infection, and other immune-related diseases. Since two different panels were evaluated, we classified patients into two groups so that appropriate panel could be tested based on clinical symptoms and medical records. Due to the variety of allergen types included in the panel of four assays and lack of sufficient sample volume in some patients, different samples were analyzed by different numbers of analyzers with various combinations of allergens. Therefore, only pairs of matched allergens by the same sample were compared among four analyzers.

2.2. In vitro allergen-specific IgE measurements {#s0020}
------------------------------------------------

Serum aliquots were tested by four different systems; AdvanSure AlloScreen (LG Life Science, Seoul, Korea), AdvanSure Allostation Smart II (LG Life Science, Seoul, Korea), PROTIA Allergy-Q (ProteomeTech, Seoul, Korea), and RIDA Allergy Screen (R-Biopharm, Darmstadt, Germany). All the test procedures were performed following the manufacture's instruction. Although detection ranges were various among four analyzers, results were identically classified into 7 levels and were interpreted as class 0--6 in all analyzers ([Table 1](#t0005){ref-type="table"}).Table 1Specifications of four different MAST analyzers.Table 1.AdvanSure AlloScreenAdvanSure Allostation Smart IIPROTIA Allergy-QRIDA Allergy ScreenManufacturerLG Life Science (Korea)LG Life Science (Korea)ProteomeTech (Korea)R-Biopharm (Germany)InstrumentAdvanSure™ AllostationAdvanSure™ Allostation Smart IIQ-stationAlleRoboTReagentAdvanSure™ AlloscreenAdvanSure™ AlloscreenPROTIA™ Allergy-QAlleisaScreen®PrincipleImmunoblotImmunoblotImmunoblotImmunoblotClass stratificationClass 0--6Class 0--6Class 0--6Class 0--6Degree of automationSemi automationFull automationFull automationFull automationNumber of antigens -Total (common)60 (20)90 (30)70 (18)80 (40) -Food panel40604460 -Inhalant panel40604460Minimal sample volume (μl)100250120800Tested sample volume (μl)10010050300Number of strips utilized2212Capacity or number of tests per run24304836Analysis time (hr)3.54.04.03.8Analysis time per sample (min)8.75856.3

2.3. Inter-method comparison of four analyzers {#s0025}
----------------------------------------------

We compared a pair of analyzers each time in order to maximize the comparison efficiency because different allergen lists are available by four analyzers. Furthermore, we focused on comparison of two specific analyzers (AdvanSure AlloScreen versus AdvanSure Allostation Smart II), because AdvanSure Allostation Smart II is the upgraded version of AdvanSure AlloScreen, both of which are developed by the same manufacturer (LG Life Science). Afterwards, we compared two newly introduced analyzers (i.e. AdvanSure Allostation Smart II and PROTIA Allergy-Q) with currently widely utilized assay (RIDA Allergy Screen) as reference values.

2.4. Comparison among different cut-off levels for positive interpretation {#s0030}
--------------------------------------------------------------------------

No standardized specific cut-off level for positive result is defined worldwide until today [@bib17]. Moreover, previous studies which compared various MAST assays utilized different cutoff levels. For instance, several studies used class 1 as the cutoff level for positive results [@bib8], [@bib11], [@bib12], whereas class 2 was adopted as the cutoff level for positive results in other studies [@bib6], [@bib10], [@bib32]. Considering the natural characteristics of semi-quantitative results in MAST assays, comparison of different cut-off levels in the paired results might provide clinical clues for more precise diagnostic interpretation. Therefore, we applied cut-off levels of class 1, class 2, and class 3 as minimal requirement for positive results for all comparison analyses.

2.5. Statistical analysis {#s0035}
-------------------------

We analyzed the concordance degree by calculating total agreement percentage following the same methodology used in a previous study [@bib18]; total agreement percentage=(total number of results−number of discrepancies)×100/total number of results. Additionally, concordant positive rates were calculated with the proportions of agreement for positive responses because low frequency of positive results can affect the total agreement percentage. Furthermore, agreement of detection results between two analyzers was determined by Cohen\'s kappa analysis [@bib19]. Finally, the presence of propensity toward positive results in specific assay for certain allergen was determined when the difference between discrepant results accounted for over 10% of all pairs. For example, when assay A and assay B are compared for allergen C, \[(number of samples with A positive, B negative result)−(number of samples with A negative, B positive result)\]×100/ total number of results ≥10% can be interpreted as the positive propensity of assay A for allergen C compared to assay B.

For all statistical analyses, we used MedCalc 11.0 (MedCalc Software, Belgium) and SPSS 18.0 (SPSS Inc., Chicago, IL).

3. Results {#s0040}
==========

3.1. Characteristics of study participants and paired sets {#s0045}
----------------------------------------------------------

The serum samples from a total of 53 and 104 patients were tested for food panel and inhalant panel in this study. Characteristics of study participants are summarized in [Table 2](#t0010){ref-type="table"}. Although several patients presented multiple allergic symptoms, urticaria was the most common clinical feature for participants in food panel while allergic rhinitis was the most frequent clinical symptoms for participants in inhalant panel. As mentioned earlier, different numbers of matched pairs were compared in each comparison analysis among four analyzers.Table 2Characteristics of study participants.Table 2.Food panelInhalant panelTotal number53104Demographic characteristics Number of male (%)21 (39.6)56 (53.8) Age, median \[1Q, 3Q\]32 \[9,55\]35 \[20.8, 56.5\] Age, range1--855--78 Number of pediatric patients (%)[a](#tbl2fna){ref-type="table-fn"}16 (30.2)24 (23.1)Clinical symptoms and signs Urticaria (%)32 (60.4)3 (2.9) Dermatitis (%)14 (26.4)1 (1.0) Allergic rhinitis (%)5 (9.4)87 (83.7) Allergic bronchitis (%)1 (1.9)4 (3.8) Asthma (%)2 (3.8)5 (4.8) Anaphylaxis or angioedema (%)6 (11.3)1 (1.0) Others (%)8 (15.1)[b](#tbl2fnb){ref-type="table-fn"}4 (3.8)[c](#tbl2fnc){ref-type="table-fn"}Matched pairs in each comparison AlloScreen vs. Allostation Smart II4390 Allostation Smart II vs. RIDA3079 Allergy-Q vs. RIDA4093[^1][^2][^3]

3.2. Comparison between AdvanSure AlloScreen and AdvanSure Allostation Smart II for evaluation of upgrade {#s0050}
---------------------------------------------------------------------------------------------------------

When we compared qualitative results between AdvanSure AlloScreen and AdvanSure Allostation Smart II, we used class 2 as the cut-off level for positive result since the manufacturer suggested the possibility of class 1 result indicating insufficient clinical significance to trigger allergic progression. A total of 43 and 90 paired serum samples were tested for 39 and 41 allergens in food and inhalant panel, respectively ([Table 3](#t0015){ref-type="table"}). All allergens showed total agreement percentages over 93.0% and 92.2% in food and inhalant panel, respectively, which indicates good concordance between old and new versions of AdvanSure assays. However, 6 allergens (*Candida albicans*, cheddar cheese, chicken, *Cladosporium herbarum*, pork, yeast) in food panel and 4 allergens (dog, egg white, mackerel, soy bean) in inhalant panel showed no concordant positive result, possibly due to rare frequency of specific IgE antibodies to these allergens among Koreans and restricted number of paired samples in this study. On the contrary, two most common allergens in both food and inhalant panels which were *Dermatophagoides pteronyssinus* and *Dermatophagoides farina* showed high total agreement percentages of over 95.0% and high agreement levels with kappa indices over 0.9. However, total agreement percentage and kappa index decreased to 93.0% and 0.8, respectively, for house dust, which was the third most common allergen.Table 3Comparison between AdvanSure AlloScreen and upgraded AdvanSure Allostation Smart II using cutoff value of class 2.Table 3.AllergenFood panelInhalant panel*N*=43*N*=90Agreement (%)Kappa indexKappa index (95% CI)Concordant positive rate (%)Agreement (%)Kappa indexKappa index (95% CI)Concordant positive rate (%)Acacia100.01.00(1.00 to 1.00)1.1*Alternaria alternata*100.01.00(1.00 to 1.00)11.6100.01.00(1.00 to 1.00)3.3Ash mix100.01.00(1.00 to 1.00)1.1*Aspergillus fumigatus*100.01.00(1.00 to 1.00)1.1Bermuda grass97.80.74(0.39 to 1.08)3.3Barley meal97.70.66(0.03 to 1.28)2.3Beef100.01.00(1.00 to 1.00)2.3Birch-Alder mix97.70.79(0.39 to 1.19)4.796.70.38(−0.17 to 0.93)1.1Buck-wheat100.01.00(1.00 to 1.00)2.3*Candida albicans*100.0NA0.0Cat95.30.64(0.18 to 1.10)4.792.20.50(0.18 to 0.81)4.4Cheddar cheese100.0NA0.0Chicken100.0NA0.0Citrus mix100.01.00(1.00 to 1.00)2.3*Cladosporium herbarum*97.70.00(0.00 to 0.00)0.098.90.66(0.04 to 1.28)1.1Cockroach97.70.79(0.39 to 1.19)4.797.80.74(0.39 to 1.09)3.3Codfish100.01.00(1.00 to 1.00)2.3Crab93.00.54(0.10 to 0.99)4.796.70.39(−0.15 to 0.93)1.1*D. farinae*95.30.91(0.78 to 1.03)48.8100.01.00(1.00 to 1.00)35.6*D. pteronyssinus*100.01.00(1.00 to 1.00)51.295.60.91(0.81 to 1.00)35.6Dandelion98.90.66(0.04 to 1.28)1.1Dog93.00.38(−0.16 to 0.91)2.397.8−0.01(−0.03 to 0.00)0.0Egg white100.01.00(1.00 to 1.00)2.3100.0NA0.0Garlic97.70.79(0.39 to 1.19)4.7Goldenrod98.90.66(0.04 to 1.28)1.1Hazelnut98.90.66(0.04 to 1.28)1.1House dust93.00.82(0.63 to 1.01)23.393.30.84(0.72 to 0.96)26.7Japanese cedar98.90.66(0.04 to 1.28)1.1Japanese Hop100.01.00(1.00 to 1.00)2.398.90.66(0.04 to 1.28)1.1Mackerel97.70.66(0.03 to 1.28)2.3100.0NA0.0Milk100.01.00(1.00 to 1.00)2.396.70.81(0.59 to 1.02)7.8Mugwort95.30.48(−0.14 to 1.10)2.3100.01.00(1.00 to 1.00)1.1Oak white97.70.66(0.03 to 1.28)2.398.90.66(0.04 to 1.28)1.1Onion100.01.00(1.00 to 1.00)2.3Orchard grass96.70.56(0.12 to 1.00)2.2Oxeye daisy98.90.66(0.04 to 1.28)1.1Peach97.70.66(0.03 to 1.28)2.397.80.49(−0.11 to 1.09)1.1Peanut100.01.00(1.00 to 1.00)2.3*Penicillium notatum*100.01.00(1.00 to 1.00)2.2Pigweed100.01.00(1.00 to 1.00)2.2Pine100.01.00(1.00 to 1.00)1.1Poplar mix100.01.00(1.00 to 1.00)1.1Pork95.3−0.02(−0.06 to 0.01)0.0Ragweed97.70.79(0.39 to 1.19)4.794.40.26(−0.18 to 0.70)1.1Reed97.80.79(0.51 to 1.07)4.4Rice97.70.66(0.03 to 1.28)2.3Russian thistle96.70.65(0.29 to 1.01)3.3Rye pollens97.70.79(0.39 to 1.19)4.795.60.65(0.33 to 0.96)4.4Salmon100.01.00(1.00 to 1.00)2.3Sallow willow94.40.27(−0.15 to 0.70)1.1Shrimp93.00.54(0.10 to 0.99)4.795.60.32(−0.16 to 0.80)1.1Soy bean100.01.00(1.00 to 1.00)2.398.90.00(0.00 to 0.00)0.0Sweet vernal grass97.80.82(0.58 to 1.06)5.6Sycamore mix98.90.66(0.04 to 1.28)1.1Timothy grass97.80.79(0.51 to 1.07)4.4Tomato100.01.00(1.00 to 1.00)2.3Tuna100.0NA0.0Wheat flour97.70.79(0.39 to 1.19)4.7Yeast, bakers100.0NA0.0[^4]

3.3. Comparison of AdvanSure Allostation Smart II or PROTIA Allergy-Q with RIDA Allergy Screen applying cut-off level of class 2 {#s0055}
--------------------------------------------------------------------------------------------------------------------------------

We evaluated concordance rate of two newly developed fully automated assays (i.e. AdvanSure Allostation Smart II and PROTIA Allergy-Q) with results by RIDA Allergy Screen considered as the reference values in this study utilizing class 2 for the cut-off level for positive result ([Table 4](#t0020){ref-type="table"}). Total agreement percentages were over 90.0% in most allergens in both assays for food and inhalant panels. However, allergens with the most frequent positive results (i.e. *D. farina*, *D. pteronyssinus*, house dust, and storage mite) presented concordance rates ranging from 69.6% to 90.0% for both AdvanSure Allostation Smart II and PROTIA Allergy-Q in food panel as well as inhalant panel.Table 4Comparison of two new fully automated analyzers with RIDA Allergy Screen as a reference using cutoff level of class 2.Table 4.AllergenAdvanSure Smart II vs. RIDAPROTIA Allergy-Q vs. RIDAFood panelInhalant panelFood panelInhalant panel*N*=30*N*=79*N*=40*N*=93Agreement (%)Concordant positive rate (%)Agreement (%)Concordant positive rate (%)Agreement (%)Concordant positive rate (%)Agreement (%)Concordant positive rate (%)Acacia100.01.397.80.0*Alternaria alternata*100.016.793.71.3100.012.593.50.0Anchovy100.00.0Ash mix100.01.396.80.0*Aspergillus fumigatus*93.30.097.50.097.80.0Banana100.00.0Barley meal96.70.095.00.0Beef96.70.097.50.0Bermuda grass98.71.396.81.1Birch-Alder mix96.73.396.20.097.50.092.52.2Bromelain (CCD)93.30.092.41.3Buck-wheat100.00.095.00.0*Candida albicans*100.00.0100.00.0Cat96.70.088.62.597.50.093.52.2Cheddar cheese100.00.0100.00.0Chestnut96.70.0100.00.0Chicken100.00.0100.00.0Citrus mix100.00.097.50.0*Cladosporium herbarum*100.00.096.20.097.80.0Clam100.00.0100.00.0Cockroach96.73.397.52.592.55.095.72.2Codfish96.70.0100.00.0Crab93.30.0100.00.085.00.094.60.0Cucumber100.00.0*D. farinae*76.726.777.212.776.730.082.811.8*D. pteronyssinus*80.026.775.913.990.022.589.212.9Dandelion100.01.396.82.2Dog96.70.097.50.087.55.097.82.2Egg white100.03.398.70.0100.07.597.80.0Garlic100.00.095.00.0Goldenrod97.51.395.70.0Hazelnut100.01.398.91.1House dust73.30.069.60.078.50.0Japanese cedar98.70.0100.01.1Japanese Hop100.00.098.71.3100.00.096.80.0Kiwi100.00.0100.00.0Latex98.70.096.80.0Mackerel96.70.0100.00.095.00.098.90.0Mango100.00.0Milk100.00.086.12.5100.00.093.50.0Mugwort96.70.098.70.0100.00.098.91.1Mussel100.00.0Oak white100.03.398.70.0100.02.596.80.0Onion100.00.0Orchard grass100.01.397.81.1Oxeye daisy100.01.3100.02.2Peach96.70.097.51.3100.00.097.80.0*Penicillium notatum*96.20.097.80.0Pigweed100.01.398.91.1Pine98.70.098.90.0Poplar mix98.70.097.81.1Peanut100.00.0100.00.0Pork96.70.095.00.0Potato100.00.097.50.0Pupa, silk cocoon90.00.090.00.0Rabbit98.70.0Ragweed93.30.0100.02.597.50.098.92.2Redtop, bent grass100.01.3Reed96.20.097.80.0Rice100.00.095.00.0Russian thistle98.71.397.81.1Rye pollens100.00.093.72.595.00.098.92.2Sallow willow100.01.397.82.2Salmon96.70.0100.00.0Shrimp96.76.794.90.095.00.0100.00.0Soy bean100.00.0100.00.0100.00.0100.00.0Storage mite86.76.789.910.190.311.8Sweet vernal grass94.91.3Sycamore mix100.01.3100.02.2Timothy grass94.91.397.82.2Tomato100.00.097.50.0Tuna100.00.0100.00.0Wheat flour93.30.090.00.0Yeast, bakers100.00.0100.00.0Yellow jacket (wasp)96.20.0

Furthermore, several allergens which showed propensity toward positive result in specific assay were noticed in both comparison analyses ([Table 5](#t0025){ref-type="table"}). While AdvanSure Allostation Smart II and PROTIA Allergy-Q showed positive propensity for some allergens when compared with RIDA Allergy Screen, RIDA Allergy Screen did not show positive propensity for any allergens with 10% discrepant results. For evaluation of AdvanSure Allostation Smart II, three allergens with the highest positive propensity results were *D. farina* (23.3%, 22.8%), *D. pteronyssinus* (20.0%, 24.1%), and house dust (26.7%, 30.4%) in both food and inhalant panels. Similarly three highest positive propensity results for PROTIA Allergy-Q were observed in *D. farina* (17.2%), *D. pteronyssinus* (10.8%), and house dust (19.4%) in inhalant panel. However, *D. farina* (17.5%) and dog (12.5%) showed highest positive propensity results in food panel of PROTIA Allergy-Q. Interestingly, the allergen with largest class difference between AdvanSure Allostation Smart II or PROTIA Allergy-Q and RIDA Allergy Screen was pupa silk cocoon in food panel although it showed positive propensity of 10.0% (i.e. mean difference by class 3 in AdvanSure Allostation Smart II vs. RIDA Allergy Screen comparison and mean difference by class 5 in PROTIA Allergy-Q vs. RIDA Allergy Screen comparison).Table 5List of allergens which present positive propensity in each assay.Table 5.AllergenAdvanSure SmartII vs. RIDAPROTIA Allergy-Q vs. RIDAAdvanSure SmartII positive propensity (%)RIDA positive propensity (%)PROTIA Allergy-Q positive propensity (%)RIDA positive propensity (%)Food panel CockroachNSNS7.5NS* D. farinae*23.3NS17.5NS* D. pteronyssinus*20.0NS10.0NS DogNSNS12.5NS House dust26.7NSNSNS Pupa, silk cocoon10.0NS10.0NS Storage mite13.3NSNSNS Wheat flourNSNS10.0NSInhalant panel Birch-alder mixNSNS7.5NS Cat8.9NSNSNS CrabNSNS5.4NS* D. farinae*22.8NS17.2NS* D. pteronyssinus*24.1NS10.8NS House dust30.4NS19.4NS Milk6.3NSNS6.5 Storage mite7.6NSNSNS[^5]

3.4. Effects of lowering or raising up the cut-off level for positive result {#s0060}
----------------------------------------------------------------------------

To evaluate the effects of various cut-off levels for positive result determination, we applied two more cut-off levels other than the conventional criteria of class 2 as minimal requirement for positive result; class 1 and class 3 as cut-off levels. Total agreement percentages and concordant positive rates were fairly influenced by application of both higher and lower cut-off levels ([Fig. 1](#f0005){ref-type="fig"}, [Fig. 2](#f0010){ref-type="fig"}). Since higher cut-off level led to more negative results, concordant positive rates decreased naturally. However, the changes of total agreement percentage according to the increase in cut-off level varied among allergens by different analyzers.Fig. 1Changes of total agreement percentage and concordant positive rate according to three different cut-off levels for positive result determination in the food panels.Fig. 1Fig. 2Changes of total agreement percentage and concordant positive rate according to three different cut-off levels for positive result determination in the inhalant panels.Fig. 2

3.5. Evaluation of positive rates for unique antigens in specific analyzer {#s0065}
--------------------------------------------------------------------------

Since different analyzers include various allergens, analyzer-specific allergens present diverse frequencies among patients ([Table 6](#t0030){ref-type="table"}). Among the accretional allergens introduced in Advansure Allostation Smart II, *Acarus siro* and apple in inhalant panel showed significant positive rates of 20.0% and 8.9%, respectively, when class 1 was utilized as cut-off level. When cut-off level was increased to class 2, these positive rates decreased to 12.2% and 4.4%, respectively (data not shown).Table 6List of analyzer-specific allergens and frequencies of positive results using cut-off level of class 1.Table 6.Food panelInhalant panelAdvanSure Smart IIPROTIA Allergy-QRIDAAdvanSure Smart IIPROTIA Allergy-QRIDA*N*=40*N*=40*N*=40*N*=90*N*=93*N*=93AllergenPositivity frequency (rate, %)AllergenPositivity frequency (rate, %)AllergenPositivity frequency (rate, %)AllergenPositivity frequency (rate, %)AllergenPositivity frequency (rate, %)AllergenPositivity frequency (rate, %)Alder2 (5.0)Almond2 (5.0)Chocolate0*Acarus siro*18 (20.0)Weat flour3 (3.2)Anchovy0Celery1 (2.5)Latex0Alder2 (2.2)Banana0Cacao0Lilac0Apple8 (8.9)Chestnut1 (1.1)Maize1 (2.5)Redtop, bent grass0Cacao0Chocolate0Mushroom0Wool0English plantain1 (1.1)Clam0Sesame1 (2.5)Yellow jacket (wasp)1 (2.5)Guinea pig0Cucumber2 (2.2)Squid2 (5.0)Hamster0Kiwi1 (1.1)Hinoki cypress1 (1.1)Lilac1 (1.1)Honey bee3 (3.3)Mango0Horse3 (3.3)Mussel0Maize1 (1.1)Wool0Sesame1 (1.1)Sheep1 (1.1)

3.6. Frequency of multiple allergen positive results per patient by four different analyzers {#s0070}
--------------------------------------------------------------------------------------------

Because multiple allergen positive results might indicate cross-reactivity between similar allergens, frequency of patients with two or more positive results was analyzed according to four different analyzers. By application of class 2 as the cut-off level for positive result, AdvanSure AlloScreen and AdvanSure Allostation Smart II presented highest frequency of patients with multiple positive allergens (i.e. AdvanSure AlloScreen: *N*=30 for food panel and *N*=43 for inhalant panel, AdvanSure Allostation Smart II: *N*=23 for food panel and *N*=37 for inhalant panel) with maximum positive allergen numbers of 23 and 34 in food panel and 28 and 32 in inhalant panel, respectively.

4. Discussion {#s0075}
=============

During the last decade, there have been several remarkable introductions of new MAST assays by different manufacturers into the clinical field of allergic diseases. Accordingly, evaluation and comparison studies of these novel MAST analyzers were reported by few groups [@bib6], [@bib8]. Until today, a total of four MAST assays \[i.e. AdvanSure AlloScreen, RIDA Allergy Screen, MAST Optigen (Hitachi), and Polycheck (Biocheck)\] were frequently evaluated with each other and showed comparable clinical performances [@bib10], [@bib11], [@bib20]. Recently, Lee and colleagues presented favorable performance of newly developed PROTIA Allergy-Q [@bib12]. In this current trend, we evaluated four MAST analyzers including two newly developed and fully automated assays. This study is the first evaluation report for AdvanSure Allostation Smart II and only the second comparison study for PROTIA Allergy-Q. Also, our study is unique for evaluating upgraded version of specific assay to ensure the improvement by including both AdvanSure AlloScreen and AdvanSure Allostation Smart II.

Based on our results, most results of comparison analyses presented good concordance levels by means of total agreement percentages over 90.0%. Satisfactory agreements were observed not only in the comparison between AdvanSure AlloScreen and AdvanSure Allostation Smart II, but also in the evaluation of AdvanSure Allostation Smart II and PROTIA Allergy-Q compared with RIDA Allergy Screen. Although four allergens with the most frequent positive results, which were *D. farina*, *D. pteronyssinus*, house dust, and storage mite, showed slightly lower concordance rates, these different results could be sufficiently overcome by careful interpretation of MAST results in association with clinical manifestations.

One interesting finding we focused on in this study was positive propensity of each analyzer. In the midst of various available MAST analyzers with comparable diagnostic performance, it is important for laboratory physicians to recognize the unique propensity of each analyzer which might easily lead to positive results for particular allergen. Our study suggests that AdvanSure Allostation Smart II and PROTIA Allergy-Q are more sensitive or prone to report positive results for three common allergens (i.e. *D. farina*, *D. pteronyssinus*, and house dust) in both food and inhalant panels than RIDA Allergy Screen. Considering the multiple positive result frequencies related with cross-reactivity among similar allergens as possible mechanism for explanation [@bib21], [@bib22], [@bib23], positive propensity of each analyzer should be cautiously understood. Moreover, variations in the allergen extraction method by different manufacturers might have caused this phenomenon of diverse positive propensity in each analyzer.

Adding new allergens in the panel list is another issue for future development of MAST analyzers. Candidate allergens should be assessed based on evidences for continuous and dramatic changes in the environment and socio-behavioral lifestyle of modern individuals [@bib24], [@bib25]. At the same time, cost-effective approach is required for choices of clinically efficient allergen with reference to epidemiologic results of geographically characteristic allergen studies [@bib26], [@bib27], [@bib28], [@bib29]. Our results support the significant positive rate for *Acarus siro* among Korean population [@bib30], which is unique allergen included only in Advansure Allostation Smart II inhalant panel. Further investigations for *Acarus siro* as an inhalant allergen in general population might highlight the advantage of Advansure Allostation Smart II.

One of the most important approaches we performed in this study was the re-evaluation of cut-off levels in order to avoid false positive results. Besides the conventional cut-off level of class 2 as the minimal positive result criteria, we analyzed the changes of total agreement percentages and concordant positive rates according to cut-off level decrease to class 1 or increase to class 3. Although the increase of cut-off level seemed to make clinical circumstance more simple and concise by presenting only the definitive positive allergens, this modification resulted in lower concordant positive rates with possibility of missing potentially critical allergens. On the other hand, decrease of cut-off level produced lower total agreement percentages in most allergens, which might obscure physicians from clear identification of clinically relevant allergens. Detailed evaluation with similar approach for optimal cut-off class should be conducted for each analyzer according to specific regional frequency and distribution of allergens in the future.

A critical limitation of this study was the use of RIDA Allergy Screen assay as the reference value for evaluation of newly developed analyzers. Among the comparison studies published until today, most studies included the ImmunoCAP system (Phadia, Uppsala, Sweden) for comparison analyses as an empirically reference method [@bib8], [@bib10], [@bib11], [@bib12], [@bib20]. However, the ImmunoCAP system is neither the official nor the definite reference procedure for measurement of allergen-specific IgE antibodies despite its good reliability and reproducibility. While the ImmunoCAP system might be impractically expensive for efficient clinical service for small to medium sized clinical laboratories [@bib31], RIDA Allergy Screen assay has been continuously evaluated and reported for favorable clinical correlation with not only the ImmunoCAP system, but also serum total IgE [@bib10], [@bib32]. We anticipated that objective comparison between currently available MAST analyzers might provide sufficient information for clinical use in the practical medical field.

In conclusion, AdvanSure Allostation Smart II maintained steady concordant performance in the upgrade process from AdvanSure AlloScreen, with the uniquely extended allergen list including *Acarus siro* which showed certain positive rates. AdvanSure Allostation Smart II and PROTIA Allergy-Q presented favorable agreement performances with RIDA Allergy Screen, although positive propensities were noticed in some allergens. The conventional cut-off level of class 2 as the minimal positive result criteria appeared to be suitable for current MAST analyzers in the clinical interpretation.
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[^1]: Pediatric patients are defined as individuals with age \<20 years.

[^2]: Others include xerotic eczema, erythema multiforme, drug eruption, and insect bite.

[^3]: Others include adenoid vegetation, chronic sinusitis, and sleep apnea.

[^4]: NA: Not available.

[^5]: NS: Not significant, defined as discrepant results less than 5%.
